美国食品药品监督管理局(FDA)已正式批准IceCure Medical Ltd.开展一项名为“Choice”的上市后研究,该研究旨在评估其Prosense®冷冻消融系统在低风险乳腺癌局部治疗中的应用效果。这项批准标志着IceCure在推进冷冻消融技术临床验证方面迈出重要一步,有望为早期乳腺癌患者提供更微创的治疗选择。
美国食品药品监督管理局(FDA)已正式批准IceCure Medical Ltd.开展一项名为“Choice”的上市后研究,该研究旨在评估其Prosense®冷冻消融系统在低风险乳腺癌局部治疗中的应用效果。这项批准标志着IceCure在推进冷冻消融技术临床验证方面迈出重要一步,有望为早期乳腺癌患者提供更微创的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.